CLYM Q1 2022 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$13M

Net Income

-$13M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$162M

Total Liabilities

$7M

Stockholders' Equity

$155M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$13M	-$7M	-90.9%
Net Income	-$13M	-$19M	+29.0%